Desmopressin is used to treat bedwetting in children and nighttime urination in adults, and also helps control bleeding in certain blood disorders and replaces a missing hormone in diabetes insipidus, a condition where the body can't retain water properly.[2] DDAVP is currently approved and in use across 20 indications[4].[1]
DDAVP is one of 393 small molecule programs targeting Enuresis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
DDAVP
Halaven
MS Contin
Zolymbus
MS Contin
Effexor
Zoladex
Apatinib Mesylate
Neoadjuvant Therapy
Fentanyl Citrate
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
DDAVP
NDA NDA017922
Mar 30, 1984
DDAVP
NDA NDA018938
Dec 26, 1990
CONCENTRAID
NDA NDA019776
Mar 7, 1994
STIMATE
NDA NDA020355
Sep 6, 1995
DDAVP
NDA NDA019955
Sep 16, 2002
MINIRIN
NDA NDA021333
May 8, 2008
DESMOPRESSIN ACETATE
NDA NDA021795
Mar 3, 2017
NOCTIVA
NDA NDA201656
Jun 21, 2018
NOCDURNA
NDA NDA022517
Feb 25, 2026
DESMODA
NDA NDA219873
Sources